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Background: Primary graft dysfunction (PGD) is a significant cause of early morbidity and mortality following lung
transplantation. Improved organ preservation techniques will decrease ischemia-reperfusion injury (IRI) contributing
to PGD. Adult bone marrow-derived adherent stem cells, including mesenchymal stromal (stem) cells (MSCs) and
multipotent adult progenitor cells (MAPCs), have potent anti-inflammatory actions, and we thus postulated that
intratracheal MAPC administration during donor lung processing would decrease IRI. The goal of the study was
therefore to determine if intratracheal MAPC instillation would decrease lung injury and inflammation in an ex vivo
human lung explant model of prolonged cold storage and subsequent reperfusion.
Methods: Four donor lungs not utilized for transplant underwent 8 h of cold storage (4°C). Following rewarming
for approximately 30 min, non-HLA-matched allogeneic MAPCs (1 × 107 MAPCs/lung) were bronchoscopically instilled
into the left lower lobe (LLL) and vehicle comparably instilled into the right lower lobe (RLL). The lungs were then
perfused and mechanically ventilated for 4 h and subsequently assessed for histologic injury and for inflammatory
markers in bronchoalveolar lavage fluid (BALF) and lung tissue.
Results: All LLLs consistently demonstrated a significant decrease in histologic and BALF inflammation compared
to vehicle-treated RLLs.
Conclusions: These initial pilot studies suggest that use of non-HLA-matched allogeneic MAPCs during donor lung
processing can decrease markers of cold ischemia-induced lung injury.
Keywords: Lung transplantation, Ischemia-reperfusion injury, Cell therapy, Mesenchymal stromal cellBackground
Primary graft dysfunction (PGD) affects an estimated
10% to 25% of lung transplant recipients and is the lead-
ing cause of early posttransplantation morbidity and mor-
tality [1]. PGD, defined by poor oxygenation in the
immediate and early postoperative period, up to 72 h
after transplantation, results from multiple pathologic
mechanisms including donor lung ischemia, cold static
organ preservation, and lung ischemia-reperfusion injury
(IRI) [2]. The mechanisms of lung IRI have been extensively* Correspondence: dweiss@uvm.edu
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article, unless otherwise stated.investigated, and a common pathway is activation of in-
flammatory and immune mediators that are damaging to
the lung allograft [3,4]. Thirty-day mortality rates are
up to eightfold higher in lung transplant patients with se-
vere PGD as compared with those without PGD. Associ-
ated signs and symptoms include interstitial/alveolar
edema, increased pulmonary vascular resistance, intra-
pulmonary shunting, decreased lung compliance, and
diffuse alveolar damage (DAD). Both PGD and DAD are
associated with an earlier onset of bronchiolitis obliterans
syndrome (BOS) and chronic rejection [5-12]. Despite re-
cent advances in donor lung preservation [13], new thera-
peutic approaches to reduce IRI and thus both PGD and
chronic rejection are desperately needed [14].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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row, adipose, and other sources, including mesenchymal
stromal (stem) cells (MSCs) and multipotent adult progeni-
tor cells (MAPCs), have potent immunomodulatory prop-
erties and have been increasingly investigated in a range
of inflammatory and autoimmune conditions [15-17]. Not-
ably, both systemic and intratracheal MSC administration
reduces inflammation and injury in a wide spectrum of
preclinical lung injury models [18,19]. Further, MSCs
and MAPCs have limited immunogenicity, and thus, use
of non-HLA-matched MAPCs and MSCs is increasingly
found to be safe and potentially efficacious in a growing
spectrum of clinical disease investigations including lung
diseases [15-17]. Postulated mechanisms include release
of anti-inflammatory cytokines and conversion of macro-
phages to anti-inflammatory M2 phenotype [15-17,20].
These properties make MSCs and MAPCs particularly in-
teresting for use as a cellular therapy in solid-organ trans-
plantation [21,22].
We hypothesized that administering MSCs or MAPCs
to donor lungs would decrease potential lung inflammation
resulting from storage and handling prior to implantation
and thus decrease IRI with subsequent decrease in both
PGD and in chronic rejection. To initially assess this in a
preclinical translational pilot and feasibility study, we deter-
mined the impact of intratracheal administration of non-
HLA-matched human bone marrow-derived allogeneic
MAPCs, a cell type currently being investigated in clinical
trials in other diseases [23-27] (MultiStem®, Athersys Inc.,
Cleveland) in four human donor lungs not suitable for
transplantation using an ex vivo human lung model of
cold ischemia and subsequent reperfusion that reproduces
current approaches to organ procurement and storage.
Methods
Lung harvest and ex vivo perfusion
Following informed consent, donor lungs not suitable for
clinical use were procured under an established IRB proto-
col at The Houston Methodist (Houston Methodist Insti-
tutional Review Board protocol (2)1111-0205). The lungs
were perfused with Perfadex (Vitrolife AB, Gothenburg,
Sweden) and then stored in a refrigerator at 4°C for a total
of 8 h. Ex vivo lung perfusion (EVLP) was then performedFigure 1 Schematic of study design.with a CE-marked Vivoline LS1 perfusion system (Vivoline
Medical AB, Lund, Sweden) utilizing pH-adjusted Steen
Solution (Vitrolife AB) containing meropenem 100 mg
(AstraZeneca AB, Sodertalje, Sweden) and 10,000 U of
heparin (LEO Pharmaceutical, Copenhagen, Denmark)
(Figure 1). The lungs were initially perfused at 0.5 L/min
and then warmed over 30 min to a target of 36°C with the
flow rate increased gradually to a target of 70 mL/min
per kilogram of donor weight. When the perfusate
temperature reached 32°C, volume-controlled mech-
anical ventilation (Hamilton C2, Bonaduz, Switzerland)
was started at an initial tidal volume of 3 mL per kilogram
of donor weight with a positive end-expiratory pressure
(PEEP) level of 5 cm H2O, a rate of 7–10 breaths/min, and
a FiO2 of 0.5. Tidal volume was then increased gradually
to a maximum of 7 mL per kilogram of donor weight.
Cells and cell inoculations
Human bone marrow-derived MAPCs were isolated from
a single bone marrow aspirate, obtained with consent
from a healthy donor, and processed and extensively
characterized according to previously described methods
[23-27]. In brief, MAPCs were cultured in fibronectin-
coated plastic tissue culture flasks under low oxygen
tension in a humidified atmosphere of 5% CO2. Cells
were cultured to subconfluence in MAPC culture media
(low-glucose DMEM [Life Technologies Invitrogen] sup-
plemented with FBS [Atlas Biologicals, Fort Collins, CO],
ITS liquid media supplement [Sigma], MCDB [Sigma],
platelet-derived growth factor [R&D Systems, Minneapolis,
MN], epidermal growth factor [R&D Systems], dexametha-
sone [Sigma], penicillin/streptomycin [Life Technologies
Invitrogen], 2-phospho-L-ascorbic acid [Sigma, St. Louis,
MO], and linoleic acid-albumin [Sigma]). Cells were pas-
saged every 3–4 days, harvested using trypsin/EDTA (Life
Technologies Invitrogen, Carlsbad, CA). The cells were
positive for CD49c (90%) and CD90 (90%) and negative
for MHC class II (<1%) and CD45 (<1%) (all Abs were
from BD Biosciences, Franklin Lakes, NJ). Cells were sub-
sequently cryopreserved at population doubling 30–35 in
cryovials in the vapor phase of liquid nitrogen at a concen-
tration of 1–10 × 106 in 1 mL (PlasmaLyte, 5% HSA and
10% DMSO). Immediately prior to their use, MAPCs were
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no apparent loss of function of the MAPCs immediately
following thawing in appropriate in vitro assays. All the
studies performed to date with MAPC have used cells that
have been cryopreserved and used directly after thawing.
These include 16 publications as well as the utility in four
clinical trials for AMI, GvHD, acute stroke, and ulcerative
colitis [23-28].
Dose was determined based on prior studies with a
sheep model for ARDS that also utilized intrabronchial de-
livery of MAPC [29]. Each study lung received a dose of
107 MAPCs. Another lung inadvertently received a lower
dose (106 MAPCs) and so was not included in the overall
assessments. Given the relatively small number of lungs in
this pilot, we utilized an approach in which each lung was
its own control, comparing cell administration in one lobe
to vehicle administration in the contralateral lobe. When
each lung temperature reached approximately 32°C, cells
were thawed, diluted into 19 mL of sterile saline, and ad-
ministered by a bronchoscope into the proximal portion
of the left lower lobe (LLL) bronchus. A similar volume of
vehicle (20 mL of sterile saline) was similarly inoculated
into the proximal portion of the right lower lobe (RLL)
bronchus. Mechanical ventilation was initiated 5 min after
cell or vehicle delivery.
BAL fluid and tissue analyses
Tissue biopsies were taken using a mechanical stapler
(Covidien DST Series™ GIA™ Staplers) prior to and 2 or
4 h after cell or vehicle infusions. Care was taken to obtain
biopsies from the same areas, corresponding to the areas
of cell or vehicle instillations. After 4 h of perfusion, the
inoculated regions of the RLL and LLL were lavaged with
60 mL of saline and the BAL fluid assessed for total cell
counts and cell differentials by three blinded observers,
protein content, and levels of inflammatory cytokines de-
termined by cytokine antibody array and ELISAs (R&D
Systems, Minneapolis, MN) [30,31]. The lungs were then
fixed in 10% formalin for 1 h and a minimum of three to
four biopsies taken from the areas of instillation. Mounted
5-μm paraffin sections of each biopsy piece were evaluated
for inflammation on ten airways per animal in a blindedTable 1 Clinical characteristics of the donor lungs
Donor characteristics 1 2 3
Age 55 56 44
Sex Male Male Male
Cause of death CVA SH Asphyxiation
PaO2 at 100% FiO2 150 186 254
PEEP 10 10 10
Radiographic findings Infiltrate-edema Infiltrate-edema Infiltrate-edem
Lung appearance Edematous Edematous Edematous
CVA cerebrovascular accident, SH subarachnoid hemorrhage, MVA motor vehicle acfashion by three individuals using an established semi-
quantitative scoring system as previously described [30,31].
Lung biopsy samples were homogenized and assessed for
content of inflammatory cytokine mRNA by qPCR.
Statistical analyses
Groups were compared using either one-way or two-way
ANOVA with a Fisher’s LSD posttest or by direct analysis
between two groups by Student’s T-test, using a Welch’s
correction for unequal variances, as appropriate [30,31].
Full details for all methods are in Additional file 1.
Results
The relevant clinical characteristics of the donor lungs are
summarized in Table 1. Donor age ranged from 44 to 66,
and two of the four donor lungs were obtained from
patients with devastating neurologic events, one from
asphyxia, and one from a motor vehicle accident. All of
the lungs were not deemed suitable for transplant because
of poor functional status including low PaO2 values with a
mean of 184.8 ± 49.3 mmHg at 100% FiO2 at a PEEP of
10 mmHg. These lungs also had radiographic abnormal-
ities, variously including contusions, significant emphy-
sema, or lobar collapse that did not respond to recruitment
maneuvers in the operating room. All of the lungs also had
radiographic signs of pulmonary edema with two having
also pleural effusion, and all were noted to be variably
edematous following surgical removal. Lung #4 had RLL
collapse on CXR but expanded following removal and
bronchoscopic removal of mucus plugs.
A summary of the protocol utilized for each lung is pre-
sented in Table 2 and also in schematic form in Figure 1.
Given the small number of lungs utilized for this pilot
study, we chose to directly compare right to left lower
lobes in each lung. Appreciating that any potential lung
damage might be heterogenous, as could be best deter-
mined by gross appearance and radiographic assessments,
the right vs left lower lobes were fairly similar for each of
the lungs. Overall, the lungs had similar cold storage (8 h)
and rewarming (24.8 + 2.5 min) times and subsequently
similar reperfusion times (3.6 ± 0.8 h) following broncho-
scopic administration of cells or vehicle. At the end of the4 Mean ± SD
50 51.25 ± 5.5
Male
MVA
149 184.8 ± 49.3
10 10 ± 0
a Edema-right lower lobe collapse, right pleural effusion
Contusions, edematous
cident.
Table 2 Summary of experimental protocol
Donor lung 1 2 3 4 Mean ± SD
Duration of cold static storage (h) 8 8 8 8 8.0 ± 0
Rewarming time (min) 22 25 28 24 24.8 ± 2.5
Duration of ex vivo perfusion (h) 4 2.5 4 4 3.6 ± 0.8
Cells or vehicle delivered 107 MSC to LLL 107 MSC to LLL 107 MSC to LLL 107 MSC to LLL
Vehicle to RLL Vehicle to RLL Vehicle to RLL Vehicle to RLL
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edema that had developed in each lung. However, over-
all, there was less visible edema and inflammation in
the MAPC-treated (LLL) vs vehicle-treated (RLL) lobes.
Representative images are shown in Figure 2.
Histologic assessment of the lungs at the end of the re-
perfusion period demonstrated that although patches of
inflamed areas could be found in some of the MAPC-
treated LLLs, there was significantly less overall inflam-
mation in three out of the four lungs and also averaged
over all four lungs, as assessed by semi-quantitative scoring
of peribronchial, perivascular, and alveolar septal edema
and by presence of inflammatory cell infiltrates (Figure 3).
Representative photomicrographs are depicted in Figure 4.
Total BAL fluid cell counts were obtained in two out
of four lungs (lungs 3 and 4). In both cases, there was
a decrease of total BAL fluid cells in the MAPC-treated
LLL compared to the vehicle-treated RLL (Figure 5A).
Total BAL fluid cell counts were not obtained in the other
lungs (lungs 1 and 2) due to inadvertent laboratory error.
Cell differentials obtained on BAL fluid samples from all
four lungs demonstrated a consistent increase in neutro-
phils and eosinophils in the vehicle-treated RLL that
was ameliorated in the MAPC-treated LLL (Figure 5B).Figure 2 Representative gross appearances of the RLL and LLL of lun
while the vehicle-treated RLL appears edematous and inflamed. Black arrowMeasurements of BAL fluid total protein levels was vari-
able between the lungs, but a consistent decrease in total
protein in the MAPC-treated LLL vs vehicle-treated RLL
was observed in all four lungs (Figure 5C).
Levels of BAL fluid cytokines and chemokines demon-
strated substantial variability between the different lungs.
This included soluble anti-inflammatory mediators im-
plicated in preclinical models of MAPC actions in lung
injury and other models, such as IL-1RA, IL-10, STC,
TGS-6, and iNOS. None of these were reliably or consist-
ently increased in the MAPC-treated LLL in any of the
four lungs (data not shown). Tissue mRNA levels were
assessed in three of four lungs (lungs 2–4) by qPCR ana-
lyses of biopsy samples obtained prior to cell or vehicle
administration and then after either 2 or 4 h of reperfusion
period. Overall, patterns of tissue mRNA levels were more
consistent between the three lungs. Comparable to BAL
fluid levels of IL-10 protein, there was a strong early trend
in elevated IL-10 in the LLL with a 3.5-fold increase in the
levels of tissue IL-10 mRNA in the MAPC-treated LLL
compared to only a 1.6-fold increase in vehicle-treated
RLL as assessed at 2 h (Figure 6). Similar trends towards
increases in LLL vs RLL were also observed at 2 h in
mRNA levels of Angpt1 and STC1. Interestingly, for bothg 2 following reperfusion. The MAPC-treated LLL appears normal
s indicate areas of edema and inflammation in the RLL.
Figure 3 Semi-quantitative scoring demonstrates significant
decrease in overall inflammation in the MAPC-treated LLL
compared to the vehicle-treated RLL in three out of four lungs
and in aggregate. Means ± SD of pooled observations from three
blinded observers are depicted.
Figure 4 Representative photomicrographs from lung 1
demonstrate (A) alveolar septal thickening, edema, and
perivascular and peri-bronchial inflammatory cell infiltrates
in the control-treated RLL vs (B) minimal to no significant
inflammation in MAPC-treated LLL. Original Mag 200 × .
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expression of TSG6 from 2 to 4 h. No clear patterns of
changes were observed in mRNA levels of the other
chemokines and cytokines evaluated including TGFβ
and NOS2.
Discussion
In an initial small-scale pilot and feasibility study, we
found that airway administration of bone marrow-derived
MAPCs decreased a number of inflammatory markers
provoked by prolonged cold storage and subsequent re-
perfusion in four suboptimal donor lungs. These results
suggest that further studies to more fully investigate the
potential anti-inflammatory effects of MAPCs and MSCs
in models of IRI are warranted.
A number of different methods have been studied to
improve the viability of donor lungs and to decrease either
warm or cold ischemic inflammatory injury. These include
a flushing solution with extracellular characteristics deliv-
ered both in an antegrade and in a retrograde fashion and
the use of a portable ex vivo preservation system currently
under clinical investigation for use during transport of
donor lungs [14]. Different areas of research for therapeutic
interventions aim to modulate the response induced by
ischemia and reperfusion. For example, experimental ani-
mal models have shown a beneficial effect from gene ther-
apy delivery of IL-10 [32] and from adenosine receptor
activation [33,34]. However, while the experimental data
are promising, it is unlikely that modulating one out of
many inflammatory pathways can regulate a phenomenon
that alters several cellular mechanisms involved, as innate
and adaptive immunity, the activation of the complement
cascade, endothelial dysfunction, and the triggering of
cell death. In contrast, bone marrow-derived MSCs and
MAPCs have the unique potential of acting on multiple
inflammatory pathways involved in ischemia/reperfusion
injury.
Systemic or intratracheal administration of bone marrow-
derived MSCs or MAPCs results in decreased inflammation
and deleterious immune responses in a wide range of
preclinical inflammatory disease models including ex-
perimentally induced acute lung injuries in mouse and
in ex vivo perfused human lung models [18,19]. Further-
more, accumulating data in a growing number of clinical
trials suggest that systemic administration of non-HLA-
matched allogeneic MSCs and MAPCs is safe [23-27,35-37].
Thus, MSCs or MAPCs might conceivably be utilized to de-
crease IRI in donor human lungs with subsequent decrease
in incidence of primary graft dysfunction and longer term
complications of lung transplantation.
EVLP was originally designed as a method to assess the
quality of lungs from donation after cardiac death (DCD)
and from other nonacceptable donor lungs [38,39]. This
technique is currently under clinical trial using asanguinous
Figure 5 BAL fluid analyses. (A) Decrease in total BAL fluid cell counts in the MAPC-treated LLL in lungs 3 and 4. Total cell counts were not
assessed in lungs 1 or 2. Data represents total cell counts for each individual lung and means ± SEM of the values obtained for each lung. (B) MAPC
instillation also resulted in a significant decrease in the elevated numbers of BAL fluid total neutrophils and eosinophils in all four lungs. Data represents
means ± SEM of pooled observations from three blinded observers. *Significantly different from the corresponding LLL value. (C) BAL fluid total protein
levels were lower at the end of the perfusion period in the MAPC-treated LLL vs vehicle-treated RLL. Data represents means ± SEM.
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Figure 6 Cytokine analysis of lung tissue. qPCR analysis was performed on the lung tissue samples collected from the MAPC-treated LLL and
vehicle-treated RLL of lungs 2–4 at t = 0, 2, and/or 4 h. The fold expression represents the levels of the target gene compared to the t = 0 value.
All data were normalized to a housekeeping gene, GAPDH. Data represents means ± standard deviations from LLL and RLL samples from lungs
2–4. Although strong trends towards differences at 2 h were observed in several of the measured mRNA levels of mediators typically associated
with MSC immunomodulation, none reached statistical significance.
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tial donor lungs that under current criteria are not deemed
suitable for transplant [40]. EVLP with asanguinous perfus-
ates thus further offers an opportunity to administer MSCs
or MAPCs directly into the donor lung by either intratra-
cheal or intravascular routes prior to implantation. In an
initial proof-of-concept pilot and feasibility study using
an explant human lung model of cold ischemia and subse-
quent rewarming and reperfusion, a simple approach in-
volving bronchoscopic instillation of bone marrow-derived
MAPCs significantly decreased markers of inflammation
and injury. Intriguingly, a similar reduction in inflamma-
tory endpoints was also observed in the lower lobe of
an additional lung in which tenfold fewer MAPCs were
administered to the LLL (data not shown). These results
suggest that MAPC or MSC administration to donor lungs
may be a useful approach to both decrease PGD and also
improve viability of suboptimal donor lungs. Indeed, a
recent parallel study demonstrated that MSC administra-
tion reduced alveolar edema in failed donor human lungs
[41]. We chose to initially assess direct airway MAPC
administration into a single lobe with the contralateral
lung as comparison to directly assess effects within each in-
dividual lung. This was done as the initial injuries to these
areas appeared comparable and this was a straightforward
approach to use for a pilot study. In particular, lower lobes
tend to be most often affected by aspiration and other dam-
age in ventilated brain-dead potential donors. Overall, the
major advantage of this approach was the ability to
obtain useful pilot data out of a smaller number of
lungs. However, as the nature and degree of lung injury
can be heterogenous, future larger scale studies will usecomplementary approaches such as MAPC vs vehicle ad-
ministration in alternating whole lungs. With larger scale
studies, the lungs can be grouped accordingly to a
number of clinical factors including radiographic infil-
trates, P/F ratio, cause of death, and length of ICU stay for
example.
The cold ischemic storage (8 h of total cold storage) is
comparable to currently utilized clinical approaches. We
also chose to use “off the shelf” non-HLA-matched MAPCs
as proof of feasibility. Given the short time period in which
transplantation needs to occur after identification of a
donor lung and suitable recipient, it is not yet feasible
to consider isolating and expanding MSCs or MAPCs
from either the donor or recipient. Further, it is conceiv-
able that MSCs or MAPCs obtained from patients with
lung diseases may be adversely affected by the underlying
pathophysiologic mechanisms. Nonetheless, given clinical
variability between lungs and lobes within each lung and
the relatively small sample size, the current pilot data is
still compelling in its consistency of an ameliorating effect
of MAPC administration in reducing BAL fluid total cell
counts, protein, and histologic inflammation.
These findings need to be further explored, clarified,
and validated in a larger number of lungs and under dif-
ferent paradigms of cold storage injury conditions, dose
and timing of cell administration, and experimental
approaches involving MAPC vs vehicle administration
to alternating lungs as compared to lobar comparisons
within each lung. Future studies will also investigate
conditioned media and microsomal particles produced
by the cells to see if these can convey similar effects.
Physiologic endpoints including alveolar fluid clearance, as
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tration in ex vivo perfused human lungs [40], and oxygen-
ation will be included. Future studies will further assess
MSC effects on endothelial injury in the perfused lungs.
We did not assess localization, clearance or removal of the
MAPCs from the donor lungs, or the effect of the lung en-
vironment on MAPC function, but these also need to be
evaluated. Assessment in preclinical models of lung trans-
plantation will also provide critical correlative information.
If the pilot results are validated, this approach may be a
simple and effective means of decreasing IRI.
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